Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Pharmaceuticals and Diagnostics segments. The Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Roche Holding’s (NASDAQ:RHHBY) key blockbuster drugs – Herceptin and Avastin – will lose their market exclusivity in 2019, while another blockbuster drug, Rituxan, has already lost its exclusivity. These three drugs are important for Roche as they generate $21 billion in annual sales, representin.

Is Roche In Trouble With $21 Billion In Sales Nearing Patent Expiry?

Spark Therapeutics

Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.

Roche Extends Offer to Acquire Spark Therapeutics Yet Again

Abbott Labs

Bristol-Myers

Eli Lilly

Novartis

Cancer-fighting stocks receive a boost from advance research and development. These five stocks can add value to your portfolio.

5 Cancer-Fighting Stocks to Add to Your Portfolio

Five Cancer-Fighting Stocks to Add to Your Portfolio

Roche Holding  and Spark Therapeutics  announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark again extend $4.3 billion takeover offer

Roche (RHHBY) wins EU approval for its immuno-oncology drug Tecentriq in combination with Abraxane to treat metastatic triple-negative breast cancer, which is a difficult-to-treat disease.

Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer

adidas AG

BASF SE

Deutsche Telekom AG

This post is from Benzinga's Partner Content team As August winds down, so too does the second quarter earnings season.

What Some Of The Largest Companies On OTC Markets Said In Their Most Recent Earnings Reports

Roche Holding’s (NASDAQ:RHHBY) Herceptin is the leading targeted therapy for the treatment of metastatic HER2 positive breast cancer. HER2 positive breast cancer refers to a type of breast cancer, in which the cells have higher than normal levels of HER2, which is a protein called human epidermal.

Can Roche's Blockbuster Drug Herceptin's Sales Grow?

Accenture Plc

Adobe

Disney

Home Depot

McDonald's

Microsoft

PepsiCo

Procter & Gamble

Total

Fast food and oil companies top the list of socially responsible investing stocks? Learn the surprising reasons why.

The 10 Biggest SRI Stocks

Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.

Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer

Seadrill Partners LLC (SDLP) CEO John Roche on Q2 2019 Results - Earnings Call Transcript

Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.

Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC

VKTX produced strong data in reducing liver fat in NAFLD patients.

Roche Sets An Immunotherapy First With Tecentriq Combination: Looks To Increase Sales

The Hanover Insurance Group (THG) CEO Jack Roche on Q2 2019 Results - Earnings Call Transcript

Roche  and Spark Therapeutics  announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue.

Roche, Spark extend $4.3 billion takeover again, this time to September 3

Roche delivered better than expected second quarter results, with the company's portfolio of newer drugs really shining in terms of growth.

Strong Growth In New Drugs Propelling Roche

Amgen

AstraZeneca

Johnson & Johnson

Merck

Pfizer

Thermo Fisher Scientific

The fight against cancer is a big battle. And these 10 companies are among the biggest combatants you can invest in.

10 Biggest Cancer-Fighting Stocks

Roche Holding AG (RHHBY) CEO Severin Schwan on Q2 2019 Results - Earnings Call Transcript

Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

AbbVie

Bayer AG

Sanofi

Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright

The Street seems to have shifted towards a more positive stance on Roche, with estimates, price targets, and sentiment all more positive than just a few months ago.

Roche Getting A Little More Benefit Of The Doubt

Exelixis

Exelixis (EXEL) adds four cohorts and expands two cohorts in the early-stage study evaluating lead drug, Cabometyx, in combination with Tecentriq.

Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study

Roche Holding (NASDAQ:RHHBY) acquired Genentech, a pharmaceuticals company with three blockbuster oncology drugs, in 2009 for a sum of $47 billion. Back in 2008, Genentech’s top drugs were Avastin, Rituxan, Herceptin, and Lucentis, which generated sales of over $7 billion.

Was The $47 Billion Acquisition of Genentech In 2009 A Good Deal For Roche?

Allergan

Celgene

Vertex Pharmaceuticals

Biotech companies exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.

News for Roche Holding AG Stock (RHHBY)